1
|
Scott D, Li H, Harvey Y, Chan F, Mottok A, Boyle M, Evens A, Schoder H, Straus D, Bartlett N, Sweetenham J, Barr P, Fanale M, Hsi E, Cook J, Kahl B, Leonard J, Friedberg J, Leblanc M, Steidl C, Gascoyne R, Rimsza L, Press O. THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_81] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- D.W. Scott
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - H. Li
- SWOG Statistical Centre; Fred Hutchison Cancer Research Centre; Seattle USA
| | - Y. Harvey
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - F. Chan
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - A. Mottok
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - M. Boyle
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - A.M. Evens
- Tufts Cancer Center; Tufts Medical Center; Boston USA
| | - H. Schoder
- Molecular Imaging and Therapy Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - D.J. Straus
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - N.L. Bartlett
- Department of Medicine; Washington University School of Medicine; St. Louis USA
| | - J.W. Sweetenham
- Huntsman Cancer Institute; University of Utah; Salt Lake City USA
| | - P.M. Barr
- Wilmot Cancer Institute; University of Rochester; Rochester USA
| | - M.A. Fanale
- Department of Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - E.D. Hsi
- Department of Laboratory Medicine; Cleveland Clinic; Cleveland USA
| | - J.R. Cook
- Department of Laboratory Medicine; Cleveland Clinic; Cleveland USA
| | - B.S. Kahl
- Department of Medicine; Washington University School of Medicine; St. Louis USA
| | - J.P. Leonard
- Department of Medicine; Weill Cornell Medical College; New York USA
| | - J.W. Friedberg
- Wilmot Cancer Institute; University of Rochester; Rochester USA
| | - M. Leblanc
- SWOG Statistical Centre; Fred Hutchison Cancer Research Centre; Seattle USA
| | - C. Steidl
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - R.D. Gascoyne
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - L.M. Rimsza
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Scottsdale USA
| | - O.W. Press
- Clinical Research Division; Fred Hutchison Cancer Research Centre; Seattle USA
| |
Collapse
|
2
|
Lane D, Chiu D, Su F, Srinivasan S, Kern H, Press O, Stayton P, Convertine A. Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents. Polym Chem 2015; 6:1286-1299. [PMID: 26097514 PMCID: PMC4470501 DOI: 10.1039/c4py01250j] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Aqueous reversible addition-fragmentation chain transfer (RAFT) polymerization was employed to prepare a series of linear copolymers of N,N-dimethylacrylamide (DMA) and 2-hydroxyethylacrylamide (HEAm) with narrow Đ values over a molecular weight range spanning three orders of magnitude (103 to 106 Da). Trithiocarbonate-based RAFT chain transfer agents (CTAs) were grafted onto these scaffolds using carbodiimide chemistry catalyzed with DMAP. The resultant graft chain transfer agent (gCTA) was subsequently employed to synthesize polymeric brushes with a number of important vinyl monomer classes including acrylamido, methacrylamido, and methacrylate. Brush polymerization kinetics were evaluated for the aqueous RAFT polymerization of DMA from a 10 arm gCTA. Polymeric brushes containing hydroxyl functionality were further functionalized in order to prepare 2nd generation gCTAs which were subsequently employed to prepare polymers with a brushed-brush architecture with molecular weights in excess of 106 Da. These resultant single particle nanoparticles (SNPs) were employed as drug delivery vehicles for the anthracycline-based drug doxorubicin via copolymerization of DMA with a protected carbazate monomer (bocSMA). Cell-specific targeting functionality was also introduced via copolymerization with a biotin-functional monomer (bioHEMA). Drug release of the hydrazone linked doxorubicin was evaluated as function of pH and serum and chemotherapeutic activity was evaluated in SKOV3 ovarian cancer cells.
Collapse
Affiliation(s)
| | | | - F.Y. Su
- Molecular Engineering and Sciences Institute, Department of Bioengineering, Box 355061, Seattle, WA, 98195, USA
| | - S. Srinivasan
- Molecular Engineering and Sciences Institute, Department of Bioengineering, Box 355061, Seattle, WA, 98195, USA
| | - H.B. Kern
- Molecular Engineering and Sciences Institute, Department of Bioengineering, Box 355061, Seattle, WA, 98195, USA
| | - O.W. Press
- Molecular Engineering and Sciences Institute, Department of Bioengineering, Box 355061, Seattle, WA, 98195, USA
| | - P.S. Stayton
- Molecular Engineering and Sciences Institute, Department of Bioengineering, Box 355061, Seattle, WA, 98195, USA
| | - A.J. Convertine
- Molecular Engineering and Sciences Institute, Department of Bioengineering, Box 355061, Seattle, WA, 98195, USA
| |
Collapse
|
3
|
Kenoyer A, Orozco J, Hamlin D, Wilbur D, Fisher D, Hylarides M, Axtman A, Frayo S, Green D, Gopal A, O'Donnell P, Press O, Pagel J. Haploidentical Bone Marrow Transplantation Using Anti-CD45 Radioimmunotherapy to Decrease Relapse in a Pre-Clinical Murine Model. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
4
|
Zhang W, Gordon M, Yang D, Yun J, Press O, Rhodes K, Groshen S, Lenz H. Genomic Polymorphisms of Angiogenesis Pathway Predict Radiosensitivity in Rectal Cancer. Int J Radiat Oncol Biol Phys 2005. [DOI: 10.1016/j.ijrobp.2005.07.485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Gordon MA, Zhang W, Karaman M, Yun J, Press O, Rhodes K, Vallböhmer D, Iqbal S, Hacia J, Lenz HJ. Gene expression profiling associated with risk of recurrence in patients with colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - W. Zhang
- Univ of Southern CA, Los Angeles, CA
| | | | - J. Yun
- Univ of Southern CA, Los Angeles, CA
| | - O. Press
- Univ of Southern CA, Los Angeles, CA
| | - K. Rhodes
- Univ of Southern CA, Los Angeles, CA
| | | | - S. Iqbal
- Univ of Southern CA, Los Angeles, CA
| | - J. Hacia
- Univ of Southern CA, Los Angeles, CA
| | | |
Collapse
|
6
|
Affiliation(s)
- K. E. Rhodes
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| | - D. Vallböhmer
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| | - W. Zhang
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| | - D. Y. Yang
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| | - J. Yun
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| | - O. Press
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| | - M. Gordon
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| | - S. Iqbal
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| | - H.-J. Lenz
- USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA
| |
Collapse
|
7
|
Zaucha R, Holmberg L, Maloney D, Press O, Bensinger W. BEAM vs BuMelTT high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell infusion (HSCT) in the treatment of non-Hodgkin’s lymphoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Zaucha
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - L. Holmberg
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - D. Maloney
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - O. Press
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - W. Bensinger
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| |
Collapse
|
8
|
Zhang W, Gordon M, Yun J, Press O, Yang D, Groshen S, Lenz H. Association between dinucleotide repeat(CA) polymorphism of nuclear factor kappa-bata(NF-KB) and local recurrence of stage II/III rectal cancer patients treated with chemoradiation. Int J Radiat Oncol Biol Phys 2004. [DOI: 10.1016/j.ijrobp.2004.07.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Yun J, Zhang W, Park D, Yang D, Press O, Gordon M, Mallik N, Lenz HJ. Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Yun
- University of Southern California, Los Angeles, CA
| | - W. Zhang
- University of Southern California, Los Angeles, CA
| | - D. Park
- University of Southern California, Los Angeles, CA
| | - D. Yang
- University of Southern California, Los Angeles, CA
| | - O. Press
- University of Southern California, Los Angeles, CA
| | - M. Gordon
- University of Southern California, Los Angeles, CA
| | - N. Mallik
- University of Southern California, Los Angeles, CA
| | - H. J. Lenz
- University of Southern California, Los Angeles, CA
| |
Collapse
|
10
|
Mallik N, Zhang W, Yang DY, Iqbal S, Yun J, Press O, Gordon M, Lenz HJ. Polymorphisms in IL-8 and the GSTP1 are associated with survival of metastatic colorectal cancer patients treated with CPT-11. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. Mallik
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - W. Zhang
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - D. Y. Yang
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - S. Iqbal
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - J. Yun
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - O. Press
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - M. Gordon
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - H.-J. Lenz
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| |
Collapse
|
11
|
Park DJ, Yun J, Yang DY, Iqbal S, Press O, Groshen S, Gordon M, Zhang W, Lenz HJ. Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3627] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. J. Park
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - J. Yun
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - D. Y. Yang
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - S. Iqbal
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - O. Press
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - S. Groshen
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - M. Gordon
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - W. Zhang
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - H.-J. Lenz
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| |
Collapse
|
12
|
Gordon MA, Zhang W, Yang DY, Gil J, Yun J, Press O, Mallik N, Lenz HJ. MnSOD and GPx-1 polymorphisms in relation to local recurrence in patients with rectal cancer treated with chemoradiation. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. A. Gordon
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - W. Zhang
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - D. Y. Yang
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - J. Gil
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - J. Yun
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - O. Press
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - N. Mallik
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | - H. J. Lenz
- USC Norris Comprehensive Cancer Center, Los Angeles, CA
| |
Collapse
|
13
|
Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R, Maloney D, Chauncey T, Appelbaum F, Bensinger W. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32:279-85. [PMID: 12858199 DOI: 10.1038/sj.bmt.1704110] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We evaluated prognostic factors and treatment outcome of patients with relapsed/refractory Hodgkin's disease (HD) receiving autologous stem cell transplantation (ASCT). In total, 92 patients received total body irradiation, cyclophosphamide and etoposide (TBI/CY/E) (n=42) or busulfan, melphalan and thiotepa (Bu/Mel/T) (n=50) supported with ASCT. A total of 33 (66%) patients receiving the Bu/Mel/T regimen had a prior history of dose-limiting irradiation. Mucositis, hepatic and pulmonary toxicities were the main causes of morbidity and mortality, irrespective of the conditioning regimen. The transplant-related mortality was 15%. With a median follow-up of 6 years (range 2.5-11), the cumulative probabilities of survival, event-free survival (EFS) and relapse at 6 years were 55, 51 and 32%. The 6-year Kaplan-Meier (KM) probabilities of EFS for patients with less advanced disease (patients in first chemotherapy-responsive relapse or second remission (n=42)) and more advanced disease (all other patients (n=50)) were 60 and 44%. No differences in toxicities and efficacy between the conditioning regimens were found. ASCT is an effective treatment for patients with refractory/relapsed HD. Female patients and patients with less advanced disease at transplant had a better outcome. Patients with prior irradiation benefited from the Bu/Mel/T regimen.
Collapse
Affiliation(s)
- F Gutierrez-Delgado
- Fred Hutchinson Cancer Research, Veterans Administration Hospital, University of Washington, Seattle, WA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000; 15:15-29. [PMID: 10740649 DOI: 10.1089/cbr.2000.15.15] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Pretargeted radioimmunotherapy (PRIT) was investigated in patients with non-Hodgkin's lymphoma (NHL). The PRIT approach used in this study is a multi-step delivery system in which an antibody is used to target streptavidin to a tumor associated antigen receptor, and subsequently biotin is then used to target 90Y radioisotope to the tumor localized streptavidin. A chimeric, IgG1, anti-CD20 antibody, designated C2B8 or Rituximab, was conjugated to streptavidin (SA) and administered to patients with NHL. Thirty-four hours later, a clearing agent, synthetic biotin-N-acetyl-galactosamine, was administered to remove non-localized conjugate from the circulation. Finally, a DOTA-biotin ligand, labeled with 111In for imaging and/or 90Y for therapy was administered. Ten patients with relapsed or refractory NHL were studied. In three patients, the C2B8/SA conjugate was radiolabeled with a trace amount of 186Re in order to assess pharmacokinetics and biodistribution using gamma camera imaging. Seven patients received 30 or 50 mCi/m2 90Y DOTA-biotin. Re-186 C2B8/SA images confirmed that the conjugate localized to known tumor sites and that the clearing agent removed > 95% of the conjugate from the circulation. Radiolabeled biotin localized well to tumor. Unbound radiobiotin was rapidly excreted from the whole body and normal organs. The mean tumor dose calculated was 29 +/- 23 cGy/mCi 90Y and the average whole body dose was 0.76 +/- 0.3 cGy/mCi 90Y, resulting in a mean tumor to whole body dose ratio of 38:1. Only grade I/II non-hematologic toxicity was observed. Hematologic toxicity was also not severe; i.e., five of the seven patients who received 30 or 50 mCi/m2 of 90Y-DOTA-biotin experienced only transient grade III (but no grade IV) hematologic toxicity. Although six of ten patients developed humoral immune responses to the streptavidin, these were delayed and transient and hence may not preclude retreatment. Six of seven patients who received 30 or 50mCi/m2 90Y achieved objective tumor regression, including three complete and one partial response. The estimate of tumor to whole body dose ratio (38:1) achieved with PRIT in these NHL patients is higher than has been achieved in other studies using conventional RIT. Toxicity was mild and tumor response encouraging. PRIT clearly deserves additional study in patients with NHL.
Collapse
Affiliation(s)
- P L Weiden
- Virginia Mason Medical Center, Seattle, WA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, Press O, Maloney DG, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94:4029-35. [PMID: 10590046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34-selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant. Seven patients (22.6%) developed CMV disease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.
Collapse
Affiliation(s)
- L A Holmberg
- Clinical Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Fefer A, Robinson N, Benyunes MC, Bensinger WI, Press O, Thompson JA, Lindgren C. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. Cancer J Sci Am 1997; 3 Suppl 1:S48-53. [PMID: 9457394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
PURPOSE Autologous or allogeneic bone marrow transplantation (BMT) or stem cell transplantation (SCT) for advanced hematologic malignancies is associated with a high relapse rate. It has been postulated that recombinant interleukin-2 (rIL-2) administered as consolidative immunotherapy early after BMT or SCT, at a time of minimal residual disease, might reduce the relapse rate. We review here preliminary results from a series of studies designed to investigate the safety, immunomodulatory effects, and clinical benefits of rIL-2 therapy following autologous and allogeneic BMT and SCT. PATIENTS AND METHODS Patients with hematologic malignancies underwent autologous or allogeneic BMT or SCT and received rIL-2 by continuous intravenous infusion a median of 33 to 56 days later. In all trials, the rIL-2 regimen consisted of a moderate induction dose for 4 to 5 days in the hospital, 4 to 6 days of rest, and a low maintenance dose for 10 days in the outpatient setting. A phase I trial of Roche rIL-2 after autoBMT, a feasibility trial of autologous lymphokine-activated killer cells with rIL-2, and another phase I/II trial of Chiron rIL-2 after autoBMT were performed. A similar phase I trial of IL-2 after alloBMT was also performed in children with acute leukemia beyond first complete remission. RESULTS An rIL-2 regimen has been identified that can be tolerated early after transplantation. Administration of this rIL-2 regimen induces marked increases in CD3+CD8+ T lymphocytes and CD3-CD56+ natural killer cells and enhances their antitumor cytolytic activity. Encouraging but somewhat inconsistent clinical outcomes were noted in phase I/II trials in patients with lymphoma and acute myeloid leukemia. CONCLUSIONS The results of phase I/II trials are sufficiently encouraging to justify prospectively randomized phase III trials to determine whether rIL-2 after autologous SCT will reduce the rate of posttransplantation relapse and improve survival in patients with advanced hematologic malignancies.
Collapse
Affiliation(s)
- A Fefer
- University of Washington School of Medicine, Division of Medical Oncology, USA
| | | | | | | | | | | | | |
Collapse
|
17
|
Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3:261-6. [PMID: 9450921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The purpose of this study was to evaluate the efficacy of high-dose chemotherapy with busulfan (Bu), melphalan (Mel), and thiotepa (TT), and of autologous peripheral blood stem cell (PBSC) infusion in patients with aggressive non-Hodgkin's lymphoma (NHL) or relapsed Hodgkin's disease (HD). Forty patients, 23 with intermediate (n= 18) or high-grade (n=5) NHL and 17 with HD received Bu (12 mg/kg), Mel (100 mg/kg), TT (450-500 mg/m2) [corrected], and autologous PBSC infusion. Of 27 patients with more advanced disease, 16 had primary refractory disease, 8 were in refractory relapse, and 3 were in third remission. Of 13 patients with less advanced disease, 7 were in untreated or responding first relapse and 3 were in second remission, whereas 3 with high-grade NHL were in first remission. Twenty-nine patients (73%) had received prior radiotherapy (RT) prohibiting a total-body irradiation (TBI)-based conditioning regimen. The projected 2-year probabilities of survival, event-free survival, and relapse for all patients were 0.60, 0.46, and 0.31 (0.85, 0.85, and 0.15 for patients with less advanced disease and 0.48, 0.30, and 0.37 for patients with more advanced disease). The probability of nonrelapse mortality in the first 100 days was 0.17. Severe idiopathic pneumonia syndrome was not observed in any patients with less advanced disease and in only one patient with more advanced disease. A regimen of BuMelTT is well tolerated in patients with aggressive NHL or relapsed HD, and results obtained to date are at least equivalent to other published regimens, including TBI-based regimens. This regimen appears to be a particularly attractive alternative for patients who have already received dose-limiting RT and should be evaluated further in prospective, randomized studies.
Collapse
Affiliation(s)
- K Schiffman
- Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Robinson N, Benyunes MC, Thompson JA, York A, Petersdorf S, Press O, Lindgren C, Chauncey T, Buckner CD, Bensinger WI, Appelbaum FR, Fefer A. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplant 1997; 19:435-42. [PMID: 9052908 PMCID: PMC7092324 DOI: 10.1038/sj.bmt.1700687] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate. It is postulated that IL-2 administered after ASCT may eliminate minimal residual disease and thereby reduce relapses. A phase I/II study was performed to identify a regimen of IL-2 (Chiron) that could be given early after ASCT in phase III trials. In the phase I study, beginning a median of 46 days after ASCT for hematologic malignancy, cohorts of three to four patients received escalating doses of 'induction' IL-2 of 9, 10, or 12 x 10(6) IU/m2/day for 4 or 5 days by continuous i.v. infusion (CIV), followed by a 4-day rest period, and then 1.6 x 10(6) IU/m2/day of maintenance IL-2 by CIV for 10 days. The maximum tolerated dose (MTD) of induction IL-2 was 9 x 10(6) IU/m2/day x 4. In the phase II study, 52 patients received the MTD. Eighty percent of patients completed induction IL-2. Most patients exhibited some degree of capillary leak. One patient died of CMV pneumonia and one died of ARDS. Maintenance IL-2 was well tolerated. In the phase I/II study, 16 of 31 patients with non-Hodgkin lymphoma (NHL), 3/8 with Hodgkin disease (HD), 4/17 with AML, and 4/5 with ALL remain in CR. Two of six multiple myeloma (MM) patients remain in PR. Although the regimen of IL-2 identified had significant side-effects in some patients, it was well tolerated in the majority of patients. Phase III prospectively randomized clinical trials are in progress to determine if this IL-2 regimen will decrease the relapse rate after ASCT for AML and NHL.
Collapse
Affiliation(s)
- N Robinson
- Department of Medicine, University of Washington, the Fred Hutchinson Cancer Research Center, Seattle 98195, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
|
20
|
Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12:2559-66. [PMID: 7989929 DOI: 10.1200/jco.1994.12.12.2559] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
PURPOSE To evaluate a high-dose treatment regimen of fractionated total-body irradiation (TBI), etoposide, and cyclophosphamide (Cy) followed by autologous stem-cell transplantation (ASCT) in patients with malignant lymphoma. PATIENTS AND METHODS Fifty-three patients with non-Hodgkin's lymphoma (NHL; n = 43) or Hodgkin's disease (HD; n = 10) received 12.0 Gy of fractionated TBI, etoposide 60 mg/kg, and Cy 100 mg/kg followed by infusion of autologous hematopoietic stem cells. RESULTS Thirty-one of 53 patients are alive a median of 643 (range, 177 to 1,144) days after transplant. The 2 year Kaplan-Meier (K-M) estimates of survival, event-free survival (EFS), and relapse for all 53 patients were 54%, 45%, and 43%, respectively. Sixteen of 24 patients with less advanced disease and 10 of 29 patients with more advanced disease survive free of disease for K-M estimates of EFS of 61% and 31%, respectively (P = .006). The K-M estimates of relapse were 34% for patients with less advanced disease and 53% (P = .05) for patients with more advanced disease. The K-M estimates of dying from causes other than relapse were 8% in patients with less versus 25% in patients with more advanced disease (P = .09). CONCLUSION These data indicate that approximately 60% of patients transplanted early after failure of initial therapy for malignant lymphoma are projected to be disease-free more than 2 years after treatment with fractionated TBI, etoposide, and Cy and infusion of autologous hematopoietic stem cells. The transplant-related mortality rate is low and relapse is the main cause of treatment failure in patients with less advanced disease. For patients with more advanced disease, the K-M estimates of both transplant-related deaths (25%) and relapse (53%) remain major problems.
Collapse
Affiliation(s)
- C H Weaver
- Fred Hutchinson Cancer Research Center, Seattle, WA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993; 11:1329-35. [PMID: 8315430 DOI: 10.1200/jco.1993.11.7.1329] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
PURPOSE To evaluate high-dose chemotherapy followed by autologous bone marrow transplantation (ABMT) in patients with lymphoid malignancy who had received prior radiation therapy. PATIENTS AND METHODS Fifty-seven patients with non-Hodgkin's lymphoma (NHL; n = 23), Hodgkin's disease (HD, n = 32), or acute lymphoblastic leukemia (ALL; n = 2) with a history of previous radiation therapy were treated with cyclophosphamide (Cy; 7.2 g/m2), carmustine (300 mg/m2 or 600 mg/m2), and etoposide (2,400 mg/m2) (CBV) followed by ABMT. RESULTS The projected 2-year probabilities of survival, event-free survival (EFS), and relapse were .31, .24, and .76, respectively. For patients with intermediate- and high-grade lymphoma and HD the probabilities were .27, .10, and .14 for EFS and .57, .90, and .77 for relapse. The probability of nonrelapse mortality in the first 100 days post-ABMT was 33%. Idiopathic pneumonia syndrome (IPS) was observed in no patients who received carmustine 300 mg/m2 and 23% of patients who received carmustine 600 mg/m2 (P = .05). Eight-three percent of patients who received mediastinal radiation therapy less than 3 months before transplant developed IPS, compared with 13% who received radiation therapy more than 3 months before transplant (P = .001). CONCLUSION ABMT following high-dose CBV resulted in long-term disease-free survival in 25% of patients with lymphoid malignancies who had previously received dose-limiting radiation therapy. Fatal IPS and a high relapse rate were major factors limiting successful outcome following ABMT. The morbidity and mortality rates associated with the administration of carmustine 600 mg/m2 were prohibitively high, especially in patients who received mediastinal radiation immediately before ABMT, and were not associated with a decrease in post-ABMT relapse.
Collapse
Affiliation(s)
- C H Weaver
- Fred Hutchinson Cancer Research Center, Seattle, WA 98104
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Geissler F, Anderson SK, Venkatesan P, Press O. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 1992; 52:2907-15. [PMID: 1581908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The endocytosis and degradation of 125I-labeled anti-mu monoclonal antibody DA4-4 by a Burkitt's lymphoma cell line was investigated using biochemical, chromatographic, electrophoretic, radioautographic, and electron microscopic techniques. 125I-DA4-4 was rapidly internalized by Ramos cells and routed from endosomes to lysosomes. Proteolysis of radiolabeled antibodies began in a late endosomal compartment, but lysosomes were primarily responsible for the terminal degradation of 125I-DA4-4. Catabolism of 125I-DA4-4 could be inhibited by 74-95% by blocking its delivery to late endosomes and lysosomes by incubation at 18 degrees C, by neutralizing the pH in intracellular organelles with monensin or ammonium chloride, or by inhibiting lysosomal enzymes with leupeptin. Radiolabeled antibodies synthesized using the chloramine T or Iodo-Gen techniques were degraded three times faster than conjugates made using a nonmetabolizable 125I-tyramine cellobiose adduct. Five major intermediate metabolites (Mr 48,000, 42,000, 25,000, 15,000, and 10,000) were generated during the intracellular catabolism of 125I-DA4-4, but 125I-tyrosine was responsible for 95% of the small-molecular-weight metabolites released by cells into the culture medium. We anticipate that a full comprehension of the catabolism of radiolabeled antibodies by tumor cells will make possible the development of clinical interventions which will enhance the retention of radioimmunoconjugates by hematologic malignancies and improve the efficacy of radioimmunotherapy.
Collapse
Affiliation(s)
- F Geissler
- Department of Biological Structure, University of Washington, Seattle 98195
| | | | | | | |
Collapse
|
23
|
De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992; 52:1916-23. [PMID: 1348016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/25/2023]
Abstract
The HER-2/neu oncogene encodes a Mr 185,000 transmembrane phosphoglycoprotein which is overexpressed in 25-35% of breast and ovarian neoplasms and portends a poor prognosis. We have studied the feasibility of targeting this oncoprotein, designated p185, with radioiodinated murine monoclonal antibodies (muMABs) 4D5 and 7C2, which recognize distinct epitopes on its extracellular domain. The rates of internalization and catabolism of these antibodies were analyzed by cellular radioimmunoassay and electron microscopy. After binding to NIH3T3 HER-2/neu cells, which show high surface expression of p185, the muMABs were endocytosed via coated pits, routed to lysosomes, and degraded. Approximately 44% of 125I-4D5 and 39% of 125I-7C2 were catabolized by tumor cells after 24 h. The biodistribution of radiolabeled 4D5 and 7C2 were evaluated in beige/nude mice bearing s.c. NIH3T3 HER-2/neu grafts. A high specificity of localization was seen with tumor:organ ratios of activity generally ranging from 5:1 to 30:1. However, the percentage injected dose of radioactivity per gram of tumor declined sharply from 25% at 24 h to 5% at 120 h postinjection. Treating the animals with 400-700 muCi 131I-4D5 caused a marked inhibition of tumor growth, although no mice were cured. Unlabeled 4D5 had no effect on tumor progression in this model, but administering 400-700 muCi of 131I-DA4-4, an isotype-matched irrelevant muMAB, resulted in an intermediate degree of growth retardation. Analysis of kinetic blood data and whole-body time-activity curves indicated that the irrelevant conjugate remained in the body 2-3 times longer than 131I-4D5. Radioiodinated anti-HER-2/neu muMABs are attractive agents for radioimmunodiagnosis and radioimmunotherapy of aggressive HER-2/neu-positive breast and ovarian carcinomas, but effective strategies for retarding intratumoral catabolism may be necessary to optimize their clinical utility.
Collapse
Affiliation(s)
- K De Santes
- Department of Pediatrics, University of Washington, Seattle 98195
| | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
The endocytosis and intracellular metabolism of radiolabeled anti-CD3 MoAb 64.1 by the malignant human T cell line HPB-ALL were studied using biochemical, morphological, electrophoretic, and chromatographic techniques. Biosynthetically labeled [3H]64.1 and externally radioiodinated 125I-64.1 were similarly internalized and degraded by tumor cells, with approximately 70% of the initially bound radioactivity being released to the culture supernatant as trichloroacetic acid-soluble radioactivity in the first 24 hr of culture. Radiolabeled 64.1 was routed from the cell membrane to endosomes where initial proteolysis began and finally to lysosomes where terminal catabolism to single amino acids occurred. SDS-PAGE demonstrated four major intracellular metabolite species (46, 25, 15, and less than 10 kDa). Thin-layer chromatography demonstrated that greater than 95% of the trichloroacetic acid-soluble radioactivity in culture supernatants was 125I-monoiodotyrosine, indicating that proteases, not deiodinases, were of primary importance in catabolism of 125I-64.1. In the presence of inhibitors of lysosomal function (leupeptin, monensin, and ammonium chloride), 125I-64.1 degradation was impeded, causing prolonged retention of radioactivity in the lysosomal compartment of cells. However, although the pace of catabolism was markedly diminished by these agents, no major changes in the sizes of intermediate metabolites generated were observed. Our results suggest that judicious administration of lysosomal inhibitors (e.g. chloroquine, verapamil, monensin) may significantly enhance retention of radioimmunoconjugates by lymphoid malignancies, improving radioimmunoscintigraphic and radioimmunotherapeutic efforts.
Collapse
Affiliation(s)
- F Geissler
- Department of Biological Structure, University of Washington, Seattle 98195
| | | | | |
Collapse
|
25
|
Ali S, Warren S, Badger C, Eary J, Press O, Krohn KA, Nelp WB. Synthesis and radioiodinatton of aryl-carbohydrate compounds for attachment to monoclonal antibodies. J Labelled Comp Radiopharm 1989. [DOI: 10.1002/jlcr.25802601138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
26
|
Martin PJ, Hansen JA, Torok-Storb B, Moretti L, Press O, Storb R, Thomas ED, Weiden PL, Vitetta ES. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3:437-44. [PMID: 2973360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Data from human clinical trials and animal experiments have suggested that T lymphocytes in donor marrow help to facilitate engraftment after allogeneic bone marrow transplantation, possibly through a suppressive effect on the immunity of the recipient. In previous studies marrows from HLA-identical donors were treated ex vivo with a mixture of eight monoclonal antibodies together with rabbit complement to achieve a 3-log depletion of T cells and CD3-negative lymphoid cells. Transplantation of this marrow was associated with a 27% actuarial risk of graft failure in leukemic recipients conditioned with cyclophosphamide (120 mg/kg) and 15.75 Gy fractionated total body irradiation. In the present study, we employed an anti-CD3 ricin A-chain-containing immunotoxin (64.1-A) together with 20 mM NH4Cl to achieve a selective 3-log depletion of CD3-positive cells. The patient entry criteria and pretransplant conditioning regimen were identical to those used in previous studies. Despite the differences in marrow treatment, the clinical outcome of the present study was similar to that obtained previously. Graft-versus-host disease (GVHD) was largely prevented without the need for post-transplant immunosuppression, but two of the eight patients developed graft failure. These results indicate that CD3-negative cells have little or no ability to initiate GVHD. To the extent that graft failure in this study was not caused by stem cell damage or loss of CD3-negative cells during ex vivo processing of the marrow, it appears that the lymphoid cells required for facilitating allogeneic engraftment under these conditions are CD3-positive.
Collapse
Affiliation(s)
- P J Martin
- Fred Hutchinson Cancer Research Center, Seattle, WA 98104
| | | | | | | | | | | | | | | | | |
Collapse
|